Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor for moderate COVID-19 in hospitalized cancer patients
ACTRN12620000841976Phase 3Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Selinexor with Placebo (2 arms). Started Sep 2021; status: completed.
02
Drugs
selinexor
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12620000841976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000841976.